Royalty Pharma revenue and financials
$56.44Change from previous close: −0.39%Absolute change: −$0.22
In the fiscal year ended December 2025, Royalty Pharma reported revenue of $2.38B (+5.06% year over year). Net income was $770.95M, a net margin of 32.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.06%
- 2025 vs 2024
- Net income growth
- −10.25%
- 2025 vs 2024
- Net margin
- 32.4%
- 2024: 37.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total assets | 19,621 | 18,223 | 16,382 | 16,813 | 17,516 | 16,020 |
| Current assets | 1,528 | 1,802 | 1,274 | 2,555 | 2,878 | 2,697 |
| Cash and equivalents | 619 | 929 | 477 | 1,711 | 1,541 | 1,009 |
| Short-term investments | 18.8 | 58.2 | 18.3 | 25.7 | 648 | — |
| Receivables | 884 | 811 | 761 | 728 | 683 | — |
| Net property, plant and equipment | 19.1 | — | — | — | — | — |
| Goodwill | 925 | 0.0 | — | — | — | — |
| Other intangible assets | — | 5.3 | 1.8 | 14.5 | 5.7 | — |
| Long-term investments | 880 | 1,260 | 1,012 | 736 | 910 | — |
| Current liabilities | 636 | 1,254 | 161 | 1,167 | 171 | 308 |
| Accounts payable | 19.4 | 13.4 | 15.2 | 7.9 | 5.6 | — |
| Long-term debt | 8,951 | 7,612 | 6,135 | 7,116 | 7,096 | 5,817 |
| Total debt | 8,951 | 7,612 | 6,135 | 7,116 | — | — |
| Total liabilities | 9,906 | 7,880 | 6,298 | 7,288 | 7,267 | 6,124 |
| Total equity (incl. minority) | 9,715 | 10,342 | 10,084 | 9,525 | 10,249 | — |
| Retained earnings | 2,356 | 2,846 | 2,518 | 1,965 | 2,255 | — |
| Minority interest | 3,238 | 3,396 | 3,558 | 3,897 | 4,472 | — |